, Protection personnelle antivectorielle (PPAV)

P. La, un répulsif pour vêtements, une moustiquaire, et l'utilisation de la climatisation) a été prescrite chez 84,3 % des voyageurs séniors (n=349)

, La prescription d'une PPAV a été observée avec la répartition suivante : 92,5 % (n=173) pour les voyageurs vers l'Afrique sub-saharienne, 95,6 % (n=65) pour les voyageurs vers l'Amérique du Sud et 92,8 % (n=64) pour les voyageurs vers l

, On n'observait pas de différence significative sur l'indication d'une prescription de PPAV selon la présence ou l'absence d'un antécédent chez le voyageur sénior (p=0,66)

, % (n=70) des voyageurs sans pathologie chronique contre 46 % (n=116) avec pathologie chronique, vol.43

. Vii and . Bibliographie, UNWTO Tourism Highlights, Organisation Mondiale du Tourisme, vol.1, 2018.

R. W. Wieten, M. Van-der-schalie, B. J. Visser, M. P. Grobusch, and M. Van-vugt, Risk factors and pre-travel healthcare of international travellers attending a Dutch travel clinic: a crosssectional analysis, Travel Med Infect Dis. oct, vol.12, issue.5, pp.511-535, 2014.

V. K. Jaeger, N. Tschudi, R. Rüegg, C. Hatz, and S. Bühler, The elderly, the young and the pregnant traveler --A retrospective data analysis from a large Swiss Travel Center with a special focus on malaria prophylaxis and yellow fever vaccination, Travel Med Infect Dis. déc, vol.13, issue.6, pp.475-84, 2015.

S. Bühler, R. Rüegg, R. Steffen, C. Hatz, and V. K. Jaeger, A profile of travelers -an analysis from a large swiss travel clinic, J Travel Med, vol.21, issue.5, pp.324-355, 2014.

C. Aubry, J. Gaudart, C. Gaillard, J. Delmont, P. Parola et al., Demographics, health and travel characteristics of international travellers at a pre-travel clinic in Marseille, France, Travel Med Infect Dis. sept, vol.10, issue.5-6, pp.247-56, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01307761

S. Mittelholzer-null and . Null, Stürchler null. Malaria Prophylaxis in Different Age Groups, J Travel Med. 1 déc, vol.3, issue.4, pp.219-242, 1996.

N. Mühlberger, T. Jelinek, R. H. Behrens, I. Gjørup, J. P. Coulaud et al., Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. 36. 15 avr, vol.8, pp.990-995, 2003.

E. J. García-rivera and J. G. Rigau-pérez, Dengue severity in the elderly in Puerto Rico, Rev Panam Salud Publica. juin, vol.13, issue.6, pp.362-370, 2003.

P. Gautret, J. Gaudart, K. Leder, E. Schwartz, F. Castelli et al., Travel-Associated Illness in Older Adults (>60 y), J Travel Med. 1 mai, vol.19, issue.3, pp.169-77, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01313286

R. W. Wieten, T. Leenstra, A. Goorhuis, M. Van-vugt, and M. P. Grobusch, Health Risks of Travelers With Medical Conditions -A Retrospective Analysis, J Travel Med. avr, vol.19, issue.2, pp.104-114, 2012.

S. Stienlauf, B. Streltsin, E. Meltzer, E. Kopel, E. Leshem et al., Chronic illnesses in travelers to developing countries, Travel Med Infect Dis. déc, vol.12, pp.757-63, 2014.

M. Darrat and G. T. Flaherty, Retrospective analysis of older travellers attending a specialist travel health clinic, Trop Dis Travel Med Vaccines, vol.5, p.17, 2019.

S. Stienlauf, E. Meltzer, D. Kurnik, E. Leshem, E. Kopel et al., Potential drug interactions in travelers with chronic illnesses: a large retrospective cohort study, Travel Med Infect Dis. oct, vol.12, issue.5, pp.499-504, 2014.

M. Kaml, I. Weiskirchner, M. Keller, T. Luft, E. Hoster et al., Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers, vol.24, pp.6808-6819, 2006.

K. Goodwin, C. Viboud, and L. Simonsen, Antibody response to influenza vaccination in the elderly: a quantitative review, Vaccine. 20 févr, vol.24, issue.8, pp.1159-69, 2006.

E. Rafferty, P. Duclos, S. Yactayo, and M. Schuster, Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review, Vaccine. 2 déc, vol.31, issue.49, pp.5798-805, 2013.

S. O. Driessen, F. G. Cobelens, and R. J. Ligthelm, Travel-related morbidity in travelers with insulindependent diabetes mellitus, J Travel Med. mars, vol.6, issue.1, pp.12-17, 1999.

K. Van-herck, P. Van-damme, F. Castelli, J. Zuckerman, H. Nothdurft et al., Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey, J Travel Med. févr, vol.11, issue.1, pp.3-8, 2004.

D. Jeannel, C. Caserio-schönemann, C. D. Morello, R. Thélot, and B. , Les décès de français lors d'un séjour à l'étranger et leurs causes, Bull Épidémiologique Hebd, pp.166-174, 2006.

N. Sbaih, B. Buss, D. Goyal, S. R. Rao, R. Benefield et al., Potentially Serious Drug Interactions Resulting From the Pretravel Health Encounter. Open Forum Infect Dis, vol.5, p.266, 2018.

G. Bonaldo, L. A. Andriani, D. 'annibali, O. Motola, D. Vaccheri et al., Cardiovascular safety of macrolide and fluoroquinolone antibiotics: An analysis of the WHO database of adverse drug reactions, Pharmacoepidemiol Drug Saf, vol.28, issue.11, pp.1457-63, 2019.

, Bulletin Epidémiologique Hebdomadaire 2019 -Recommandations sanitaires pour les voyageurs, 2019.

C. T. Supuran, Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors, Expert Opin Drug Metab Toxicol, vol.12, issue.4, pp.423-454, 2016.

N. Allen, C. Bergin, and S. P. Kennelly, Malaria in the returning older traveler, Trop Dis Travel Med Vaccines, vol.2, issue.2, 2016.

D. Alon, P. Shitrit, and M. Chowers, Risk behaviors and spectrum of diseases among elderly travelers: a comparison of younger and older adults, J Travel Med. août, vol.17, issue.4, pp.250-255, 2010.

S. Belderok, A. Van-den-hoek, W. Roeffen, R. Sauerwein, and G. Sonder, Adherence to chemoprophylaxis and Plasmodium falciparum anti-aircumsporozoite seroconversion in a prospective cohort study of Dutch short-term travelers, PloS One. févr, vol.8, issue.2, p.56863, 2013.

, Malarone (atovaquone and proguanil hydrochloride). GlaxoSmithKline, 2019.

H. Jolink, J. Den-hartigh, L. G. Visser, and C. Van-nieuwkoop, Pancytopenia due to proguanil toxicity in a returning traveller with fever, Eur J Clin Pharmacol. août, vol.66, issue.8, pp.811-813, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00587607

S. Delaigue, I. Signolet, P. H. Consigny, L. De-gentile, D. Ortenzio et al., New guidelines for the prevention of imported malaria in France, Med Mal Infect. 28 août, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02479509

M. Van-luin, M. E. Van-der-ende, C. Richter, M. Visser, D. Faraj et al., Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir, AIDS Lond Engl. 15 mai, vol.24, issue.8, pp.1223-1229, 2010.

K. Hidalgo, A. Lyles, and S. R. Dean, A potential interaction between warfarin and atovaquone, Ann Pharmacother. janv, vol.45, issue.1, p.3, 2011.

C. Kamaliddin, V. Joste, N. Argy, and S. Houze, Interaction entre la fluindione et le traitement par atovaquone-proguanil d'un paludisme à P. falciparum, Thérapie. oct, vol.73, issue.5, pp.445-452, 2018.

Y. Munera, F. C. Hugues, L. Jeunne, C. Pays, and J. F. , Interaction of thyroxine sodium with antimalarial drugs, BMJ. 31 mai, vol.314, issue.7094, p.1593, 1997.

R. Böcker, W. Mühlberg, D. Platt, and C. J. Estler, Serum level, half-life and apparent volume of distribution of doxycycline in geriatric patients, Eur J Clin Pharmacol, vol.30, issue.1, pp.105-113, 1986.

G. Houin, F. Brunner, T. Nebout, M. Cherfaoui, G. Lagrue et al., The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man, Br J Clin Pharmacol. sept, vol.16, issue.3, pp.245-52, 1983.

A. Grahnén, B. Olsson, G. Johansson, and S. A. Eckernäs, Doxycycline carrageenate--an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate, Eur J Clin Pharmacol, vol.46, issue.2, pp.143-149, 1994.

A. Garraffo, P. Dellamonica, J. P. Fournier, P. Lapalus, and E. Bernard, The effect of rifampicin on the pharmacokinetics of doxycycline. Infection, vol.16, pp.297-305, 1988.

A. Arslan, M. A. Zain, M. Mukhtar, W. Ullah, and S. Roomi, Methotrexate and doxycycline interaction: a rare cause of pancytopenia, BMJ Case Rep. 31 mai, vol.12, issue.5, p.229296, 2019.

F. Penning-van-beest, J. Koerselman, and R. Herings, Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants, J Thromb Haemost JTH. févr, vol.6, issue.2, pp.284-90, 2008.

J. Lewis, T. Gregorian, I. Portillo, and J. Goad, Drug interactions with antimalarial medications in older travelers: a clinical guide, J Travel Med, vol.27, issue.1, 2019.

J. Karbwang, N. Bangchang, K. Back, D. J. Bunnag, and D. , Effect of ampicillin on mefloquine pharmacokinetics in Thai males, Eur J Clin Pharmacol, vol.40, issue.6, pp.631-634, 1991.

W. Ridtitid, M. Wongnawa, W. Mahatthanatrakul, N. Raungsri, and M. Sunbhanich, Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers, J Clin Pharm Ther. juin, vol.30, issue.3, pp.285-90, 2005.

W. Ridtitid, M. Wongnawa, W. Mahatthanatrakul, P. Chaipol, and M. Sunbhanich, Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers, J Pharm Pharmacol, vol.52, issue.10, pp.1265-1274, 2000.

, Vaccination des personnes âgées. Haut conseil de la santé publique, HCSP, 2016.

A. Panda, F. Qian, S. Mohanty, D. Van-duin, F. K. Newman et al., Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response, J Immunol. 1 mars, vol.184, issue.5, pp.2518-2545, 2010.

F. Denis, M. Mounier, L. Hessel, J. P. Michel, N. Gualde et al., Hepatitis-B vaccination in the elderly, J Infect Dis. juin, vol.149, issue.6, p.1019, 1984.

T. P. Monath, M. S. Cetron, K. Mccarthy, R. Nichols, W. T. Archambault et al., Yellow fever 17D vaccine safety and immunogenicity in the elderly, Hum Vaccin, vol.1, issue.5, pp.207-221, 2005.

M. Martin, L. H. Weld, T. F. Tsai, G. T. Mootrey, R. T. Chen et al., Advanced age a risk factor for illness temporally associated with yellow fever vaccination, Emerg Infect Dis. déc, vol.7, issue.6, pp.945-51, 2001.

R. E. Thomas, D. L. Lorenzetti, W. Spragins, D. Jackson, and T. Williamson, The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review, Am J Trop Med Hyg. févr, vol.86, issue.2, pp.359-72, 2012.

V. D'acremont, C. Herzog, and B. Genton, Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly, J Travel Med. avr, vol.13, issue.2, pp.78-83, 2006.

B. Wolters, U. Junge, S. Dziuba, and M. Roggendorf, Immunogenicity of combined hepatitis A and B vaccine in elderly persons, Vaccine. 8 sept, vol.21, pp.3623-3631, 2003.

M. Stoffel, M. Lievens, I. Dieussaert, I. Martin, and F. André, Immunogenicity of Twinrix in older adults: a critical analysis, Expert Rev Vaccines. févr, vol.2, issue.1, pp.9-14, 2003.

T. Höhler, G. Groeger-bicanic, B. Hoet, and M. Stoffel, Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults, Vaccine. 9 févr, vol.25, issue.8, pp.1503-1511, 2007.

R. Chlibek, J. Smetana, V. Bostíková, and M. Splino, Vaccination against viral hepatitis A and B in adults aged over 40 years--antibody persistence and immune memory, Epidemiol Mikrobiol Imunol Cas Spolecnosti Epidemiol Mikrobiol Ceske Lek Spolecnosti JE Purkyne. sept, vol.60, issue.3, pp.99-108, 2011.

J. H. Mermin, J. M. Townes, M. Gerber, N. Dolan, E. D. Mintz et al., Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance, Arch Intern Med. 23 mars, vol.158, issue.6, pp.633-641, 1998.

D. J. Mills, C. L. Lau, E. J. Fearnley, and P. Weinstein, The immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule--a case series of 420 travelers, J Travel Med, vol.18, issue.5, pp.327-359, 2011.

P. Gautret, V. Vu-hai, M. J. Soavi, P. Parola, and P. Brouqui, Effet de l'âge sur les titres d'anticorps à la suite d'un protocole de vaccination antirabique post-exposition, Pathol Biol, vol.60, issue.5, pp.322-325, 2012.

J. Aguilera, A. Perrocheau, C. Meffre, and S. Hahné, Outbreak of Serogroup W135 Meningococcal Disease after the Hajj Pilgrimage, Emerg Infect Dis. août, vol.8, issue.8, pp.761-767, 2000.

A. L. Goodman, C. Masuet-aumatell, J. Halbert, and J. N. Zuckerman, Awareness of Meningococcal Disease among Travelers from the United Kingdom to the Meningitis Belt in Africa, Am J Trop Med Hyg. 6 août, vol.91, issue.2, pp.281-286, 2014.

G. Dbaibo, N. El-ayoubi, S. Ghanem, F. Hajar, V. Bianco et al., Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial, Drugs Aging. mai, vol.30, issue.5, pp.309-328, 2013.

J. P. Cramer, K. Dubischar, S. Eder, G. D. Burchard, T. Jelinek et al., Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, Vaccine, vol.31, issue.38, pp.4579-85, 2016.

, Enquête Vie Quotidienne et Santé -Résultats départementaux d'une enquête auprès des seniors, DREES, 2014.

R. Boubaker, P. Meige, C. Mialet, C. N. Buffat, M. Uwanyiligira et al., Travellers' profile, travel patterns and vaccine practices--a 10-year prospective study in a Swiss Travel Clinic, J Travel Med. janv, vol.23, issue.1, 2016.

A. Lepoutre, D. Antona, L. Fonteneau, F. Halftermeyer-zhou, C. Baudon et al., Séroprévalence des maladies à prévention vaccinale et de cinq autres maladies infectieuses en France. Résultats de deux enquêtes nationales, Bull Epidémiol Hebd. 10 déc, pp.526-560, 2008.

A. Salmon-rousseau, E. Piednoir, V. Cattoir, L. De, and A. Blanchardière, Hajj-associated infections, Med Mal Infect, vol.46, issue.7, pp.346-54, 2016.